Alirocumab, page-9

Agreed TDA and Dupilumab has serious potential to be a blockbuster -


http://www.fiercebiotech.com/story/...eneron-sanofi-push-dupilumab-phiii/2014-11-11

Fierce Biotech:
November 11, 2014 | By John Carroll

Regeneron and its close partner Sanofi have cleared the final mid-stage hurdle for dupilumab in asthma patients, with several doses hitting the trial endpoint both for a subset of patients as well as the broad population. And the ambitious development team at Regeneron now plans to hustle into a pivotal late-stage program as they continue to make swift progress with a drug that promises to tackle a trio of conditions that share a core inflammatory trigger.

GSK are providing competition:

GlaxoSmithKline ($GSK) filed for an approval of its IL-5 asthma drug mepolizumab, with Teva (reslizumab) and AstraZeneca (benralizumab) trailing along the IL-5 pathway.

with a multi billion dollar market awaiting, not to mention the relief of suffering for patients.

I just shake my head at current sp